Urinary system์€ kidney(์‹ ์žฅ, ์ฝฉํŒฅ) / ureter(์š”๊ด€) / urinary bladder(๋ฐฉ๊ด‘) / urethra(์š”๋„) ๋กœ ๊ตฌ์„ฑ๋œ๋‹ค.

1. Normal Renal Anatomy & Function

  • ์‹ ์žฅ์€ โ€œnephronโ€์ด๋ผ๋Š” ๊ธฐ๋Šฅ์  ๋‹จ์œ„๋กœ ๊ตฌ์„ฑ๋œ๋‹ค.
  • ์ฆ‰, ํ•˜๋‚˜์˜ ๋„คํ”„๋ก ์€ ๋‹ค์Œ๊ณผ ๊ฐ™์€ ๊ธฐ๋Šฅ์„ ์ˆ˜ํ–‰: ์—ฌ๊ณผ(filtration), ํก์ˆ˜(resorption), ๋‚ด๋ถ„๋น„(endocrine).
    • ๋Œ€ํ‘œ์ ์ธ ๋‚ด๋ถ„๋น„ ๊ธฐ๋Šฅ์€ renin-angiotensin-aldosterone์ด ์žˆ๋”ฐ.
    • ์†Œ๋ณ€ ๋†๋„ ์กฐ์ ˆ
    • ๊ฐ€์žฅ ์ค‘์š”ํ•œ ์—ญํ• ์€ ์ „ํ•ด์งˆ ํ‰ํ˜•์„ ๋งž์ถ”๋Š” ๊ฒƒ!


์‚ฌ๊ตฌ์ฒด์˜ ๊ธฐ๋ณธ ๊ตฌ์กฐ. ์ •์ƒ ๊ตฌ์กฐ๋ฅผ ์ž˜ ์•Œ๊ณ  ์žˆ์–ด์•ผ, ์—ผ์ฆ๊ณผ ๊ฐ™์€ ๋น„์ •์ƒ ์ƒํ™ฉ์„ ์ดํ•ดํ•  ์ˆ˜ ์žˆ๋‹ค! ์ž˜ ๊ธฐ์–ตํ•ด๋‘๊ธฐ.

  • Functions
    • ๋ฌผ๊ณผ ์ „ํ•ด์งˆ์˜ ๋†๋„ ์กฐ์ ˆ
    • ๋ถˆํ•„์š”ํ•œ ๋Œ€์‚ฌ์ฒด ๋ฐฐ์ถœ (์—ฌ๊ณผ = ํ•„์š”ํ•œ ๊ฑด ๋†”๋‘๊ณ , ํ•„์š”์—†๋Š” ๊ฑด ๋ฒ„๋ฆฐ๋‹ค!)
    • ํ˜ˆ์•• ์กฐ์ ˆ : Renin-angiotensin system์„ ํ†ตํ•ด
  • ๊ตฌ์„ฑ : kidneys - ureters - urinary bladder - urethra
    ์ „์‹  ์ˆœํ™˜์„ ํ•œ ํ˜ˆ์•ก์ด ์‹ ์žฅ์œผ๋กœ ๋“ค์–ด์˜ค๋Š”(afferent) ํ˜ˆ๊ด€ โ†’ ์‚ฌ๊ตฌ์ฒด โ†’ ์„ธ๋‡จ๊ด€์œผ๋กœ ์ด์–ด์ง€๋Š” ํ๋ฆ„์„ ์ž˜ ๋‚˜ํƒ€๋‚ธ ๊ทธ๋ฆผ.
Basic Nephron Structure
  • ์‹ ์žฅ ํ•˜๋‚˜์— ๋„คํ”„๋ก ์ด ๋ฐฑ๋งŒ ๊ฐœ ์ •๋„ ์กด์žฌ.
  • ๋„คํ”„๋ก ์ด 70% ์ด์ƒ ์ •์ƒ ๊ตฌ์กฐ์™€ ๋‹ฌ๋ผ์ ธ ๋ฒ„๋ฆฌ๋ฉด โ†’ fibrosis๋กœ ๋Œ€์ฒด๋˜๊ณ , irreversibleํ•˜๋‹ค.
  • ๋„คํ”„๋ก ์˜ ๊ตฌ์„ฑ ์š”์†Œ:
    • glomerulus โ†’ ์—ฌ๊ณผ(filtration)
    • Bowmanโ€™s capsule โ†’ collects filtrate
    • Proximal tubule โ†’ ์žฌํก์ˆ˜(reabsorption)
    • Loop of Henle โ†’ ๋‡จ์˜ ๋†์ถ•(urine concentration)
    • Distal tubule & collecting duct โ†’ ๋งˆ์ง€๋ง‰ ์žฌํก์ˆ˜์™€ ๋ฐฐ์ถœ (fine-tuning of sodium/water reabsorption)
  • Rich capilary network๋กœ ๋‘˜๋Ÿฌ์‹ธ์—ฌ ์žˆ๋‹ค. ์„ธ๋‡จ๊ด€ ์‚ฌ์ด์‚ฌ์ด์— ์กฐ๊ทธ๋งŒ ํ˜ˆ๊ด€๋“ค์ด ์กด์žฌํ•ด์„œ ์ง€์ง€, ์˜์–‘ ๊ณต๊ธ‰.
Juxtaglomerular Apparatus
  • Macula densa + Juxtaglomerular cells + Mesangial cells ์„ ํ•ฉ์ณ ์นญํ•˜๋Š” โ€˜์ง‘ํ•ฉ์ฒดโ€™.
  • ์ฃผ์š” ๊ธฐ๋Šฅ : ํ˜ˆ์••์„ ์กฐ์ ˆํ•˜๋Š” ๋‚ด๋ถ„๋น„
    • sodium concentration ์กฐ์ ˆ
      • ์‹ฌ์žฅ์—์„œ ๋“ค์–ด์˜ค๋Š” ํ˜ˆ๊ด€์—์„œ sodium์˜ ๋†๋„๋‚˜ ํ˜ˆ์•• ๋“ฑ์„ ๊ฐ์ง€(๋ชจ๋‹ˆํ„ฐ๋ง) โ†’ ํ•„์š”์— ๋”ฐ๋ผ ์ „ํ•ด์งˆ ์žฌํก์ˆ˜ ์ด‰์ง„or์–ต์ œ, ์ˆ˜๋ถ„ ์žฌํก์ˆ˜ ์ด‰์ง„or์–ต์ œํ•ด์„œ ๋†๋„๋ฅผ ์กฐ์ ˆํ•œ๋‹ค.
    • renin ๋ถ„๋น„ โ†’ RAAS system ํ™œ์„ฑํ™”์‹œํ‚ค๋Š” ์ฒซ๋ฒˆ์งธ ๊ธฐ๊ด€
    • ํ˜ˆ์•• ์กฐ์ ˆ ๊ธฐ๋Šฅ์ด ํ•ญ์ƒ ๋™๋ฐ˜๋œ๋‹ค. (์ „ํ•ด์งˆ์€ ํ•ญ์ƒ ๋ฌผ๊ณผ ๊ฐ™์ด ์›€์ง์ด๊ธฐ ๋•Œ๋ฌธ)
    • ์‚ฌ๊ตฌ์ฒด์—ฌ๊ณผ์œจ(GFR, glomerular filtration rate) ์†๋„ ์กฐ์ ˆ โ†’ ์š”๋กœ ๋ฐฐ์ถœํ•˜๋Š” ์†๋„๋ฅผ ๋†’์ด๊ฑฐ๋‚˜ ๋Šฆ์ถค โ†’ ์ฒด์•ก๋Ÿ‰ ์กฐ์ ˆ
  • ๋ฌธ์ œ๊ฐ€ ์ƒ๊ธฐ๋ฉด ์ด๋Ÿฐ ๊ธฐ๋Šฅ์ด ๋ฌด๋„ˆ์งˆ ์ˆ˜ ์žˆ๋‹ค~ (ํ•˜์ง€๋งŒ ์—ฌ๊ธฐ์— ์—ผ์ฆ์ด ์ƒ๊ธฐ๋Š” ๊ฑด ๋ณ„๋กœ ๋ณด์ง€ ๋ชปํ–ˆ๋‹ค)
Mechanisms of Urine Formation

์˜ค์คŒ ํ˜•์„ฑ์˜ ์ฃผ์š” 3๊ฐ€์ง€ ๊ณผ์ •!

  • (1) ์—ฌ๊ณผ (Glomerular filtration)
  • (2) ์žฌํก์ˆ˜ (Tubular reabsorption)
  • (3) ๋ถ„๋น„ (Tubular secretion)

โ‡’ ์˜ค์คŒ์˜ ์ตœ์ข… ๋†๋„๋Š” ADH, aldosterone ๋“ฑ ํ˜ธ๋ฅด๋ชฌ ์‹ ํ˜ธ์— ์˜ํ•ด ๊ฐ•ํ•˜๊ฒŒ ์กฐ์ ˆ๋œ๋‹ค.

2. Glomerular Diseases

Key Concepts

  • Glomerulonephritis (์‚ฌ๊ตฌ์ฒด์‹ ์—ผ) : ๋ณดํ†ต ๋ฉด์—ญ๋งค๊ฐœ์„ฑ์ด๋‹ค.
    • (1) ์ „์‹ ์— immune complex(Ab-Ag) โ†‘ : ์ „์‹  ์งˆํ™˜์— ์˜ํ•œ ๋ฉด์—ญ๋งค๊ฐœ์„ฑ
    • (2) anti-GBM(GBM ์ž๊ฐ€ํ•ญ์ฒด) โ†‘ : ์ž๊ฐ€๋ฉด์—ญ์„ฑ
  • ์กฐ์งํ•™์ ์œผ๋กœ MPGN(mesangial cell์ด ๊ณผ์ฆ์‹) / Glomerulosclerosis(๋งŒ์„ฑ)
  • Nephrotic syndrome mechanisms

1) ์‚ฌ๊ตฌ์ฒด ์งˆํ™˜์˜ pathogenesis

  • ์‚ฌ๊ตฌ์ฒด๋Š” ์—ฌ๊ณผ๋ฅผ ๋‹ด๋‹น โ†’ ๋ฌธ์ œ๊ฐ€ ์ƒ๊ธฐ๋ฉด ๋‚ด๋ณด๋‚ด์ง€ ๋ง์•„์•ผ ํ•  ๊ฒƒ๋“ค(๋ชธ์— ๊ฐ€์ง€๊ณ  ์žˆ์–ด์•ผ ํ•  ๊ฒƒ๋“ค)์ด ์†Œ์‹ค๋œ๋‹ค.
  • ์š”๊ฒ€์‚ฌ์ƒ ๋‹จ๋ฐฑ์งˆ์ด ๋งŽ์œผ๋ฉด proteinuria, RBC๊ฐ€ ๋งŽ์œผ๋ฉด hematuria
  • BUN, creatinine์ด ๋†’์•„์ง€๋ฉด uremia
  • ๋Œ€๋ถ€๋ถ„ ๋ฉด์—ญ๋งค๊ฐœ์„ฑ์ด๋‹ค (circulating immune complexes or autoantibodies)


Immune-Complex Glomerulonephritis. immunofluorescence์— ์˜ํ•ด immunoglobulin ์นจ์ฐฉ์ด ํ™•์ธ๋˜์—ˆ๋‹ค.

  • Type โ…ข hypersensitivity์— ์˜ํ•œ ๊ฒƒ์ด ๊ฐ€์žฅ ํ”ํ•˜๋‹ค.
    • immune complex๊ฐ€ ์‚ฌ๊ตฌ์ฒด์— ์ถ•์  โ†’ ๋ฉด์—ญ ๋ฐ˜์‘์— ์˜ํ•ด ๋ณด์ฒด ํ™œ์„ฑํ™” & ํ˜ธ์ค‘๊ตฌ ๋™์› โ†’ ์‚ฌ๊ตฌ์ฒด ์†์ƒ์œผ๋กœ ์ด์–ด์ง.
  • ๋œ ํ”ํ•˜๊ฒŒ๋Š” type โ…ก hypersensitivity์— ์˜ํ•ด์„œ ๋‚˜ํƒ€๋‚  ์ˆ˜๋„ ์žˆ๋‹ค. (anti-GBM antibodies์˜ ๊ฒฝ์šฐ)
  • โ‡’ ์‹ ์žฅ ํˆฌ๊ณผ์„ฑ์ด ์ฆ๊ฐ€ํ•˜๊ณ , ์ง€์†๋˜๋ฉด ๊ฒฐ๊ตญ glomerulosclerosis๋กœ ์ด์–ด์ง„๋‹ค.

2) Classfication of GN(Glomerulonephritis)

์กฐ์งํ•™์ ์œผ๋กœ ์•„๋ž˜์™€ ๊ฐ™์ด ๋ถ„๋ฅ˜ํ•  ์ˆ˜ ์žˆ๋‹ค. MPGN์ด๋ผ ํ•˜๋ฉด (mesangioproliferative๊ฐ€ ์•„๋‹ˆ๋ผ) ๋ง‰๊ณผ ์„ธํฌ ๋ชจ๋‘๊ฐ€ ์ฆ์‹ํ•˜๋Š” membranoproliferative GN์„ ์นญํ•œ๋‹ค.

์šฉ์–ด์•ฝ์–ด์ฃผ ๋ณ‘๋ณ€ ์œ„์น˜์ •์˜ ๋ฐ ํŠน์ง•
Membranous GNMGNGBM / capillary walldiffuse thickening of GBM
(๋ชจ์„ธํ˜ˆ๊ด€๋ฒฝ ๋น„ํ›„, ์„ธํฌ ์ฆ์‹์€ ์ ๋‹ค)
Mesangioproliferative GNMsPGNmesangiumexpansion of mesangial matrix and cells
Membranoproliferative GNMPGNCapillary wall + mesangiumGBM thickening + mesangial proliferation
Focal Segmental GlomerulosclerosisFSGSsegmental scarring of glomeruli


(์™ผ) Membranous GN, hyaline thickening์— ์˜ํ•ด membrane์ด ๋‘๊บผ์›Œ์กŒ๋‹ค. (์˜ค) Membranoproliferative GN, membrane๋„ ๋‘๊บผ์›Œ์กŒ์ง€๋งŒ ์„ธํฌ(mesangial cells)๊ฐ€ ํ›จ์”ฌ ์ฆ์‹ํ–ˆ๋‹ค.

โ˜‘๏ธ Other Classifications
  • Focal v. diffuse
  • Segmental vs. global
  • Acute vs.chronic

3) ์‚ฌ๊ตฌ์ฒด ๋ณ‘์ฆ์˜ ์ž„์ƒ์  ๊ฒฐ๊ณผ

  • Proteinuria : ์ž„์ƒ์ ์œผ๋กœ ์ค‘์š”์„ฑ์ด ํฌ๋‹ค. ์‚ฌ๊ตฌ์ฒด์˜ ์—ฌ๊ณผ ๊ธฐ๋Šฅ ์ƒ์‹ค์„ ์˜๋ฏธ.
    • ์‹ ์žฅ ์†์ƒ์„ ๋‚˜ํƒ€๋‚ด๋Š” ์ง€ํ‘œ์ธ ๋™์‹œ์—, ์‹ ์žฅ ์ƒํƒœ๋ฅผ ๊ณ„์† ์•…ํ™”์‹œํ‚จ๋‹ค.
  • Nephrotic syndrome : ์•„๋ž˜ 4๊ฐ€์ง€ ์ฆ์ƒ์ด ๋™๋ฐ˜๋˜์–ด ๊ด€์ฐฐ๋  ๋•Œ.
    • Marked proteinuria
    • Hypoalbuminemia (๋ฐ–์œผ๋กœ ๋งŽ์ด ๋ฐฐ์ถœ๋จ)
    • Edema (๊ทธ๋ž˜์„œ ๋ถ€์ข… - ์ •์ˆ˜์•• โ†“ & sodium retention โ†‘)
    • Hyperlipidemia
    • ( =๋ฐฐ์ถœ์ด ์ œ๋Œ€๋กœ ์ž‘๋™ํ•˜์ง€ ์•Š์•„์„œ ๋‚˜ํƒ€๋‚˜๋Š” ์ฆ์ƒ๋“ค!)
  • Hypercoagulability (๊ณผ์‘๊ณ  ๋˜ํ•œ ์‘๊ณ ์žฅ์• ๋‹ค!)
    • (๊ฐ„๋ฟ๋งŒ ์•„๋‹ˆ๋ผ) ์‹ ์žฅ ๋ฌธ์ œ์— ์˜ํ•ด์„œ๋„ ์‘๊ณ ์žฅ์• ๊ฐ€ ์ƒ๊ธด๋‹ค๋Š” ๊ฒƒ์„ ๊ธฐ์–ตํ•˜์ž.
    • ์‚ฌ๊ตฌ์ฒด ์—ฌ๊ณผ ๊ธฐ๋Šฅ ์ €ํ•˜ โ†’ antithrombin โ…ข ์œ ์ถœ ์ฆ๊ฐ€ โ†’ ๋ถˆํ•„์š”ํ•œ ํ˜ˆ์•ก ์‘๊ณ ๋ฅผ ๋ง‰์•„์ฃผ๋˜ antithrombin์ด ์†Œ์‹ค๋˜๋ฉด์„œ ๊ณผ๋„ํ•œ ํ˜ˆ์•ก ์‘๊ณ  ๋ฐœ์ƒ.

4) ๋งŒ์„ฑ - Glomerulosclerosis

  • ์‚ฌ๊ตฌ์ฒด ์†์ƒ์˜ ๋งŒ์„ฑ์  ๊ฒฐ๊ณผ.
  • fibrosis์— ์˜ํ•ด ๊ตฌ์กฐ์  ๋ณต๊ตฌ๋Š” ๊ฐ€๋Šฅํ•˜์ง€๋งŒ(collagen ์„ฑ๋ถ„์ด ์ฑ„์šด๋‹ค), ๊ธฐ๋Šฅ์  ๋ณต๊ตฌ๋Š” ๋ถˆ๊ฐ€๋Šฅํ•˜๋‹ค.
  • ๊ณ„์† ์ง„ํ–‰๋˜์–ด ์‚ฌ๊ตฌ์ฒด์˜ 3/4 ์ด์ƒ์ด ๋ง๊ฐ€์ง€๋ฉด chronic renal failure.


Glomerulosclerosis. ์ฝœ๋ผ๊ฒ ์„ฑ๋ถ„์ด ๊ฐ€๋“ ์ฑ„์›Œ ์‚ฌ๊ตฌ์ฒด ๊ตฌ์กฐ๋ฅผ ๊ฑฐ์˜ ํ™•์ธํ•˜๊ธฐ๋„ ์–ด๋ ต๋‹ค.

Role of Podocytes in Glomerular Injury

  • podocytes : ์ผ์ข…์˜ ์ƒํ”ผ์„ธํฌ, barrier intergrity๋ฅผ ์กฐ์ ˆํ•ด barrier์˜ ํ•ญ์ƒ์„ฑ์„ ์œ ์ง€ํ•œ๋‹ค.
  • podocyte๋Š” ์žฌ์ƒ์ด ์ž˜ ์•ˆ ๋œ๋‹ค. ๊ธฐ๋Šฅ์ • ํšŒ๋ณต์ด ์–ด๋ ค์›€.
  • ์น˜๋ฃŒ ๋˜ํ•œ ์ง„ํ–‰์„ ๋Šฆ์ถœ ๋ฟ,์™„์ „ํžˆ ์ •์ƒ ์ƒํƒœ๋กœ ๋Œ์•„๊ฐ€๊ธฐ๋Š” ์–ด๋ ต๋‹ค.
  • sclerosis๊ฐ€ ์ผ๋ถ€์—๋งŒ ๋จธ๋ฌผ๋Ÿฌ ์žˆ์„ ๊ฑด์ง€, ์ „์ฒด์ ์œผ๋กœ ์ƒ๊ธธ ๊ฑด์ง€ ๊ฒฐ์ •ํ•˜๋Š” ๋ฐ ์ค‘์š”ํ•˜๋‹ค.

์—ฌ๊ธฐ๊นŒ์ง€ Summary!

  • Glomerular injury โ†’ protein leakage โ†’ tubulointerstitial damage โ†’ fibrosis
  • Proteinuria is both a marker and driver of progression
  • Chronic GN leads to global glomerulosclerosis and ultimately end stage kidney
    • ์ด์ฏค ์ง„ํ–‰๋˜๋ฉด ๋ณต๊ตฌํ•  ์ˆ˜ ์—†๋Š” ์ƒํƒœ (ํˆฌ์„ ๋ฐ–์—๋Š” ๋ฐฉ๋ฒ•์ด ์—†๋‹ค.)
    • BUN, Creatinine ๋†๋„๋กœ ํ™•์ธ ๊ฐ€๋Šฅํ•˜๋ฉฐ ์š”๊ฒ€์‚ฌ์ƒ์˜ ๊ฒฐ๊ณผ๋Š” โ€˜azotemiaโ€™๋ผ๊ณ  ํ•œ๋‹ค. ์กฐ์งํ•™์  ์†Œ๊ฒฌ๊ณผ ์ƒ๊ด€๊ด€๊ณ„๋Š” ์žˆ์ง€๋งŒ ๋ฐ˜๋“œ์‹œ 1:1 ๋งค์นญ๋˜๋Š” ๊ฐœ๋…์€ ์•„๋‹ˆ๋‹ค. (ํ˜ˆ์ค‘ BUN, creatinine ๋†๋„๋ฅผ ๋ณด๊ณ ๋Š” โ€˜azotemiaโ€™, ์กฐ์งํ•™์  ์†Œ๊ฒฌ ์ƒ์˜ ํ‘œํ˜„์€ โ€˜end stage kidneyโ€™
    • 3/4 ์ด์ƒ์ด ๋ง๊ฐ€์ง€๋ฉด โ€˜end-stageโ€™๋ผ๊ณ  ํ•œ๋‹ค.
  • Early diagnosis and management can slow the disease, but are often challenging in animals : ์ง„ํ–‰์„ ๋Šฆ์ถœ ์ˆ˜๋Š” ์žˆ์œผ๋‚˜, 1์ฐจ์  ์›์ธ์„ ์ฐพ์ง€ ๋ชปํ•˜๊ฑฐ๋‚˜ ์ „์‹ ์„ฑ ๋ฌธ์ œ์ผ ๊ฒฝ์šฐ ๊ด€๋ฆฌ๊ฐ€ ์–ด๋ ค์›Œ์ง„๋‹ค.

5) Glomerular Amyloidosis

3. Tubular and Interstitial Disorders

tubule๊ณผ ๊ทธ ์ฃผ๋ณ€์˜ ๊ฐ„์งˆ์—์„œ ๋‚˜ํƒ€๋‚˜๋Š” ์งˆ๋ณ‘์— ๋Œ€ํ•ด ์‚ดํŽด๋ณด์ž.

Key Concepts

  • Acute tubular injury : ๊ธ‰์„ฑ ์†์ƒ์˜ ์›์ธ์€ ischemia or toxin์œผ๋กœ ๊ตฌ๋ถ„ํ•  ์ˆ˜ ์žˆ๋‹ค.
    • Ischemia : ์‹ ์žฅ ์ž์ฒด์˜ ๋ฌธ์ œ๊ฐ€ ์•„๋‹ˆ๋ผ ์ „์‹ ์  ๋ฌธ์ œ์ผ ์ˆ˜๋„. ํ˜ˆ์••์ด ๋‚ฎ๊ฑฐ๋‚˜, ์ „์‹  ์ˆœํ™˜์ด ์•ˆ ๋˜๊ฑฐ๋‚˜ ํ•˜๋Š” ์ด์œ ๋กœ ๋“ค์–ด์˜ค๋Š” ํ˜ˆ์•ก๋Ÿ‰ โ†“
    • Toxin : ์‹ ์žฅ ๊ตฌ์กฐ ์ž์ฒด์— ์†์ƒ์„ ์ค€๋‹ค.
  • ์–ด๋А ์ •๋„์˜ ์†์ƒ์€ ๊ทน๋ณตํ•  ์ˆ˜ ์žˆ๋Š” ์žฅ๊ธฐํŠน์ด์ ์ธ ์ค„๊ธฐ์„ธํฌ๊ฐ€ ์žˆ๋‹ค.
  • Tubulointerstitial nephritis (์„ธ๊ด€์˜ ์†์ƒ๊ณผ ํ•จ๊ป˜ ์„ธ๊ด€ ์ฃผ๋ณ€์˜ ๊ฐ„์งˆ์—๋„ ์—ผ์ฆ์„ธํฌ๊ฐ€ ์นจ์œค)
    • ์›์ธ : ํฌ๊ฒŒ ๊ฐ์—ผ์„ฑ ์›์ธ์ฒด or ๋ฉด์—ญ๋งค๊ฐœ์„ฑ
    • ๋งˆ์ฐฌ๊ฐ€์ง€๋กœ fibrosis๊ฐ€ ์ƒ๊ธฐ๊ณ  ๋งŒ์„ฑ์œผ๋กœ ์ง„ํ–‰๋  ์ˆ˜ ์žˆ๋‹ค. (๋Œ์ดํ‚ฌ ์ˆ˜ ์—†๋‹ค)
  • Viral nephritis : ๊ฐ์—ผ์„ฑ ์›์ธ์ฒด ์ค‘ ๋ฐ”์ด๋Ÿฌ์Šค์— ์˜ํ•œ ๊ฒƒ๋“ค์ด ๋งŽ๋‹ค.
  • Leptospiral nephritis : ์„ธ๊ท ์„ฑ ์›์ธ์ฒด ์ค‘ Leptospira์— ์˜ํ•œ ์‹ ์žฅ ์—ผ์ฆ์ด ํ”ํ•˜๋‹ค.

TIN์ด ๋งŽ์€๋ฐ, ์„ธ๋‡จ๊ด€์„ ๋จผ์ € ์†์ƒ์‹œํ‚ค๋Š” ์›์ธ์ฒด์ธ์ง€ ์—ผ์ฆ์„ ๊ฐ„์งˆ์— ์œ ๋ฐœํ•˜๋Š” ์›์ธ์ฒด์ธ์ง€ ์ค‘์š”

Acute Tubular Injury (ATI)
  • Acute renal failure (ARF) ์˜ ํ”ํ•œ ์ด์œ  : ์–ด๋–ค ์›์ธ์œผ๋กœ ๊ธ‰์„ฑ์œผ๋กœ ์†์ƒ๋˜๋Š” ํ˜„์ƒ์ด ๋ฐœ์ƒ (*โ€˜failureโ€™๋ผ๋Š” ํ‘œํ˜„์€ 70%? ์ด์ƒ ์†์ƒ๋˜์–ด์•ผ ์“ด๋‹ค๋Š” ์ )
  • ์„ธ๋‡จ๊ด€์„ ํ˜•์„ฑํ•˜๋Š” ์ƒํ”ผ์„ธํฌ(tubular epithelial cells)๋“ค์€ ๋Œ€์‚ฌ์ ์œผ๋กœ ํ™œ์„ฑํ™”๋˜์–ด(highly metabolically active) ์žˆ์–ด ์ทจ์•ฝํ•˜๋‹ค.
    • โ†’ ๋…์„ฑ ๋ฌผ์งˆ์˜ ๋Œ€์‚ฌ์ฒด๊ฐ€ ๋นจ๋ฆฌ ๋งŒ๋“ค์–ด์ง€๊ณ , ๊ทธ์— ์˜ํ•œ ์†์ƒ์ด๋‚˜ ๊ดด์‚ฌ๋„ ๋น ๋ฅด๊ฒŒ ์ง„ํ–‰.
  • (1์ฐจ์  ์›์ธ์ด ์ œ๊ฑฐ๋˜๊ณ ) Basement membrane์ด ์†์ƒ๋˜์ง€ ์•Š์•˜์œผ๋ฉด ์žฌ์ƒ์ด ๊ฐ€๋Šฅํ•˜๋‹ค.
Ischemic Tubular Injury
  • Hypotension, shock, severe dehydration์— ์˜ํ•ด
  • Patch(๊ทœ์น™ ์—†์ด ๋‹ค๋ฐœ์„ฑ) necrosis, ๊ทผ์œ„์„ธ๋‡จ๊ด€, ์ฒด์•ก๋Ÿ‰์ด ์ค„์—ˆ์„ ๋•Œ ์†์ƒ์ด ์ผ์–ด๋‚  ์ˆ˜ ์žˆ๋‹ค. ์„ธ๋‡จ๊ด€์ž„์„ ์•Œ ์ˆ˜ ์žˆ๋Š” ๊ตฌ์กฐ ์•ˆ์— (ARROW) ํ•ต์ด ๊ฑฐ์˜ ์‚ฌ๋ผ์ ธ ์žˆ๋‹ค. ์‘๊ณ ๊ดด์‚ฌ๊ฐ€ ์ผ์–ด๋‚จ. (ARROWHEADS)

์„ธ๋‡จ๊ด€ ์†์ƒ โ†’ cell debris๋“ค์ด ๊ฑฐ์Šฌ๋Ÿฌ ์˜ฌ๋ผ๊ฐ€์„œ(back-leak) ์‚ฌ๊ตฌ์ฒด์˜ ๊ธฐ๋Šฅ์„ ๋ฐฉํ•ดํ•  ์ˆ˜ ์žˆ๋‹ค.

์‚ฌ๊ตฌ์ฒด๋Š” ๋น„๊ต์  ๋ฉ€์ฉกํ•œ ํŽธ : ์‚ฌ๊ตฌ์ฒด ์›์ธ๊ณผ ์„ธ๋‡จ๊ด€ ์›์ธ์€ ๋น„๊ต์  ๋ณ‘๋ณ€์ด ๋…๋ฆฝ์ ์œผ๋กœ ๋‚˜ํƒ€๋‚œ๋‹ค. ๊ฐœ๋ณ„์ ์œผ๋กœ ์ง„ํ–‰๋˜๋‹ค๊ฐ€ ํ•ฉ์ณ์ง„๋‹ค. ํ˜„์žฌ๋Š” ์„ธ๋‡จ๊ด€ ์ชฝ์—๋งŒ ๋ณ‘๋ณ€์ด ์žˆ์Œ.

Toxic Tubular Injury
  • Nephrotoxins
  • ๋…์„ฑ ๋ฌผ์งˆ์— ์˜ํ•œ necrosis๋ฉด diffuse pattern
Regeneration and Recovery

์žฅ๊ธฐํŠน์ด์ ์ธ ์ค„๊ธฐ์„ธํฌ๊ฐ€ ์กด์žฌํ•˜๋Š”์ง€,

Tubulointerstitial Nephritis
  • ์ถ•์ข…๋ณ„ ์›์ธ์ฒด๋Š” ๊ผญ ์™ธ์›Œ๋‘์ž!
  • ์ฒ˜์Œ์—๋Š” ์„ธ๋‡จ๊ด€์— ๋ฌธ์ œ๊ฐ€ ์ƒ๊ธฐ๊ณ , ๊ดด์‚ฌ๋˜๊ณ , ์—ผ์ฆ์„ธํฌ๊ฐ€ ๋™์›๋˜๊ณ  (DAMPs ๋•Œ๋ฌธ์—), ์„ธ๋‡จ๊ด€ ์ฃผ๋ณ€์˜ ์‚ฌ์ด์‚ฌ์ด ๋ชจ์„ธํ˜ˆ๊ด€์— ์—ผ์ฆ์„ธํฌ๊ฐ€ ์นจ์œค โ†’ ๊ฐ„์งˆ์— ์—ผ์ฆ
  • ๊ทธ๋ž˜์„œ tubulo + interstital์ด ์„ธํŠธ
  • Acute TIN โ†’ ๋ถ€์ข…, ํ˜ธ์ค‘๊ตฌ, ๊ดด์‚ฌ๊ฐ€ ๋‚˜ํƒ€๋‚จ
  • Chronic TIN โ†’ fibrosis, ๋‹จํ•ต๊ตฌ ๊ณ„ํ†ต ์นจ์œค(lymphocytes ๋“ฑ), ์žฌ์ƒ์ด ์•ˆ๋˜๊ณ  ์œ„์ถ•๋จ(tubular atrophy)
Leptospiral Nephritis
  • ์ถœํ˜ˆ ๋ถ€์œ„ ์กด์žฌ (์ง„ํ•œ ํ˜ธ์‚ฐ์„ฑ)
  • ํ•ต์ด ๋“ฌ์„ฑ๋“ฌ์„ฑ ์กด์žฌ (์„ธ๋‡จ๊ด€ ์†์ƒ ํ™•์ธ)
  • ํ˜ˆ๊ด€ ์†์ƒ,์„ธ๋‡จ๊ด€ ์†์ƒ but ์—ผ์ฆ์„ธํฌ๊ฐ€ ๋„๋‹ฌํ•˜๊ธฐ ์ „์ผ ์ˆ˜ ์žˆ๋‹ค ์—ผ์ฆ์„ธํฌ๊ฐ€ ๊ด€์ฐฐ๋˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ๋‹ค!
  • ์ „์‹ ๊ฐ์—ผ์— ์˜ํ•œ or ์‹ ์žฅ ๋‹จ๋… ๊ฐ์—ผ์— ์˜ํ•œ leptospirosis?
    • ํ™ฉ๋‹ฌ์ด ๊ด€์ฐฐ๋˜๋ฉด ์ „์‹ ๊ฐ์—ผ ์˜์‹ฌ
Viral Nephritis
  • ๋นจ๊ฐ„ ๋ถ€๋ถ„ : ์ถœํ˜ˆ์†Œ
Chronic Interstitial Nephritis
  • interstitial fibrosis
  • mononuclear cell infiltrates : ๊ฐ„์งˆ์— ๋‹จํ•ต๊ตฌ ๊ณ„์—ด(lymphocytes, plasma cell, macrophagesโ†“ ๋“ฑ)์ด ๋งŽ์ด ์นจ์œคํ•œ๋‹ค. โ‡’ ์‚ฌ๊ตฌ์ฒด ์œ„์ถ•
  • primary lesion์ผ ์ˆ˜๋„ ์žˆ๊ณ , ์‚ฌ๊ตฌ์ฒด๋‚˜ ์„ธ๋‡จ๊ด€์†์ƒ์— ๋”ฐ๋ผ ์˜ค๊ธฐ๋„ ํ•จ (๋”ํ”ํ•จ)
Tubular and Interstitial Lesions in End-Stage Kidney Disease
  • ๋งŒ์„ฑ์ ์œผ๋กœ ์ง„ํ–‰๋˜๋ฉด
    • ์œก์•ˆ์ ์œผ๋กœ ์ผ๋‹จ ์žฅ๊ธฐ๊ฐ€์œ„์ถ•๋˜๊ณ , ๊ด‘๋ฒ”์œ„ํ•œ ์„ฌ์œ ํ™” ๋•Œ๋ฌธ์— ํ‘œ๋ฉด์ด ์šธํ‰๋ถˆํ‰
    • (๊ฐ„์ด ์ž‘์•„์ง€๋Š” ๊ฑด PSS๊ฑฐ๋‚˜, ํ›„์ฒœ์ ์ธ end-stage liver ํ˜น์€ cirrhosis) โ‡’ ์‹ ์žฅ์—์„œ๋„ ๋™์ผ. ์šธํ‰๋ถˆํ‰ํ•ด์ง€๋ฉด์„œ ํฌ๊ธฐ๋Š” ์ž‘์•„์ง.

4. Vascular and Metabolic Diseases

Key Concepts

  • ํ—ˆํ˜ˆ์— ๋Œ€ํ•œ renal infarcts,
  • ์นผ์Š˜ ๋†๋„๊ฐ€ ๋†’์•„์กŒ์„๋•Œ - hypercalcemia-induced mineralization
  • Fibrous osteodystrophy โ† renal secondary hyperparathyroidism
Renal infarction & Hemorrhage
  • ๊ฐ€์žฅ ๋ง๋‹จ๋ถ€ ํ˜ˆ๊ด€(end-arteries)์ด ๋ง‰ํžˆ๊ธฐ ๋•Œ๋ฌธ์— ๋ฐœ์ƒ
    • ๋‹ค๋ฅธ ๊ณณ์€ ์—ฌ๋Ÿฌ ๊ฐœ์˜ ํ˜ˆ๊ด€์—์„œ ๊ณต๊ธ‰๋ฐ›๋Š”๋ฐ, end-arteries๋Š” ๋”ฑ ๊ทธ ๋ถ€๋ถ„์—๋งŒ ๊ณต๊ธ‰
    • ์›์ธ: thromboembolism (์ž‘์€ ํ˜ˆ๊ด€์ด ์‰ฝ๊ฒŒ ๋ง‰ํž˜ โ†’ ๋ถ€๋ถ„์ ์ธ ํ—ˆํ˜ˆ), vasculitis, septicemia
    • ์ฒ˜์Œ์— ํ˜ˆ๊ด€ obstruction โ†’ ์ถœํ˜ˆ(wedge-shaped), ์ฒ˜์Œ์—๋Š” ๋ถ€ํ’€์–ด๋ณด์ž„ โ†’ ์„ฌ์œ ํ™”๋กœ ๋Œ€์ฒด๋˜๋ฉด์„œ ์ˆ˜์ถ•
Hypercalcemia-Induced Nephropathy
  • hypercalceima๋กœ ์‹ ์žฅ ๋ฌธ์ œ๊ฐ€ ๋ฐœ์ƒํ•  ์ˆ˜๋„ ์žˆ์ง€๋งŒ, ์‹ ์žฅ ๋ฌธ์ œ๋กœ hypercalcemia๊ฐ€ ์œ ๋ฐœ๋  ์ˆ˜๋„ ์žˆ๋‹ค.
  • ์›์ธ:
    • Primary hyperparathyroidism โ†’ ๋ผˆ์˜ ์žฌํก์ˆ˜๊ฐ€ ๋Š˜์–ด๋‚˜ ์นผ์Š˜ ๋†๋„ ์ฆ๊ฐ€
    • Paraneoplastic syndrome โ†’ hyperparathyroidism ๊ฐ™์€ ํšจ๊ณผ
      • PTHrP-producing tumors : lymphoma, apocrine gland adenocarcinoma of the anal sac)
    • Vitamin D toxicosis
    • Chronic Renal failure (๋งŒ์„ฑ ์‹ ๋ถ€์ „ โ†’ phosphate์˜ ๋ฐฐ์ถœ ๊ฐ์†Œ(ํ˜ˆ์ค‘ ๋†๋„ ์ฆ๊ฐ€) โ†’ ์นผ์Š˜๊ณผ ๊ฒฐํ•ฉํ•˜๋ ค๊ณ  ํ•จ โ†’ ํ˜ˆ์ค‘ ์นผ์Š˜ ๋†๋„ ๊ฐ์†Œ โ†’ ๋ถ€๊ฐ‘์ƒ์ƒ˜์—์„œ PTH ๋ถ„๋น„ โ†’ ca2+ ์ ‘ํ•ฉ์ฒด๊ฐ€ ๋” ๋Š˜์–ด๋‚จ โ†’ ํ™”ํ•ฉ๋ฌผ์ด ๋Œ์•„๋‹ค๋‹ˆ๋ฉด์„œ ์—ฐ๋ถ€์กฐ์ง(ํŠนํžˆ ์‹ ์žฅ; ์‹ ์„ธ๋‡จ๊ด€, ํ˜ˆ๊ด€)์— ์นจ์ฐฉ
  • ๋งŒ์„ฑ์œผ๋กœ ์ด์–ด์ง€๋ฉด ์‹ฌํ•œ fibrosis, renal dysfunction์œผ๋กœ ์ด์–ด์ง.

์–ด๋–ค ์†Œ๊ฒฌ์„ ๋‚˜ํƒ€๋‚ผ ์ˆ˜ ์žˆ๋Š”์ง€

CKD์—์„œ ๋นˆํ˜ˆ
  • ์กฐํ˜ˆ์„ ์ด‰์ง„ํ•˜๋Š” erythropoietin ์ด ๋ถ„๋น„๊ฐ€ ์•ˆ ๋˜๋‹ค ๋ณด๋‹ˆ ๋นˆํ˜ˆ์ด ์˜ค๊ฒŒ ๋œ๋‹ค..
  • ์—ฌ๋Ÿฌ ์ž„์ƒ์ฆ์ƒ : ํ—ˆ์•ฝ, ์ ๋ง‰ ์ฐฝ๋ฐฑ, ๋ฌด๊ธฐ๋ ฅ

5. Renal Failure and End-Stage Kidney

End-stage kidney ๋ผ๋Š” ํ‘œํ˜„์€ ํ˜•ํƒœํ•™์  ๋ช…๋ช…์ด๋‹ค. Renal Failure์€ ์œก์•ˆ ํŒ๋‹จ ์ „์— ํŒ๋‹จ ๊ฐ€๋Šฅ. BUN โ†‘ & Creatinine โ†‘ โ‡’ renal failure (Azotemia๋ฅผ ํŒ๋‹จํ•˜๋Š” ์ˆ˜์น˜)

์ผ๋‹จ ์ง„๋‹จ. ๊ฐ€์žฅ ์ค‘์š”ํ•œ ์ง€ํ‘œ๋Š” BUN & Creatinine

  • BUN : urea์—์„œ ๋งŒ๋“ค์–ด์ ธ ๊ฐ„์—์„œ ๋Œ€์‚ฌ๋œ ๋ฌผ์งˆ. ํ˜ˆ์ค‘ ๋†๋„๋ฅผ ํ†ตํ•ด ์‹ ์žฅ ์†์ƒ์„ ์•Œ ์ˆ˜ ์žˆ๋‹ค. generalํ•œ azotemia marker. ์ƒ์Šนํ•˜๋ฉด azotemia.
  • Creatinine : GFR, ์‚ฌ๊ตฌ์ฒด๊ธฐ๋Šฅ ํ‰๊ฐ€(์—ฌ๊ณผ)์— ์ข€ ๋” ํŠน์ด์ ์ธ ๋งˆ์ปค.

BUN์€ ์–ด๋””์— ์ƒ๊ด€์žˆ๋“  generalํ•˜๊ฒŒ ๋†’๋‹ค. Creatinine์€ ์‚ฌ๊ตฌ์ฒด ๊ธฐ๋Šฅ์— ๋”ฐ๋ผ ๋‹ค๋ฅด๋‹ค โ†’ ๋น„์œจ ํ™•์ธ ๊ฐ€๋Šฅ

  • Prerenal : ํ˜ˆ์•ก๋Ÿ‰ ์ž์ฒด๊ฐ€ ์ค„๊ฑฐ๋‚˜โ€ฆ ์‚ฌ๊ตฌ์ฒด ๋ฌธ์ œ๊ฐ€ ์•„๋‹ˆ๋ผ๋ฉด BUN์€ ์ƒ์Šนํ•˜์ง€๋งŒ, creatinine์€ ๋น„๊ต์  ์ •์ƒ.
  • Renal : BUN & Creatinine ๋‘˜ ๋‹ค ์ƒ์Šน. (BUN/Creatinine = ~10-20:1)
  • Postrenal :
์‹ ๋ถ€์ „

Key Concepts

  • Uremia ; Azotemia์™€ ์–ด๋–ป๊ฒŒ ๋‹ค๋ฅธ์ง€
  • ๊ธ‰์„ฑ : ์ž ์žฌ์ ์œผ๋กœ๋Š” ํšŒ๋ณต์ด๋‚ญ
  • ๋งŒ์„ฑ
  • uremia, azootemia โ†’ ๋…์„ฑ๋Œ€์‚ฌ์‚ฐ๋ฌผ ^- ์ž„์ƒ์ ์œผ๋กœ ๋‚˜
AzotemiaUremia (์š”๋…์ฆ)
ํ˜ˆ์•ก์ˆ˜์น˜์ƒ BUN, Creatinine์ด ์˜ฌ๋ผ๊ฐ€ ์žˆ์„ ๋•ŒClinical syndrome: ํ˜ˆ์•ก์˜ ๋ณ€ํ™”๋ฅผ ๋™๋ฐ˜ํ•œ, ์ž„์ƒ ์ฆ์ƒ์ด ๊ด€์ฐฐ๋จ
ํšŒ๋ณต์ด ๊ฐ€๋ŠฅํšŒ๋ณต ๊ฐ€๋Šฅ์„ฑ์ด ๋ณ„๋กœ ์—†์Œ
์ข…์ข… ์ฆ์ƒ์ด ์—†๊ฑฐ๋‚˜ mildํ•  ์ˆ˜ ์žˆ๋‹ค.
Biochemical abnormalityClinical condition (์ž„์ƒ ์ฆ์ƒ์ด ๋‚˜์˜ฌ ๋•Œ๋งŒ ์“ฐ๋Š”)

(์ž˜ ์•”๊ธฐํ•˜๋ฉด ์ข‹์Œ)

BUN & Creatinine์ด ๋†’์•„์ง„ ํ™˜์ž A์™€, ์กฐ๊ธˆ๋งŒ ๋†’์•„์ง„ ํ™˜์ž B โ‡’ BUN/Creatinine ์ˆ˜์น˜๊ฐ€ uremia ํŒ๋‹จ์˜ ๊ฒฐ์ •์  ๊ทผ๊ฑฐ๊ฐ€ ๋˜์ง€ ์•Š๋Š”๋‹ค.

ARF
  • ์›์ธ

    • Prerenal : ํ˜ˆ๋ฅ˜๋Ÿ‰ ๊ฐ์†Œ
    • Renal : nephrotoxins, ischemia (์‹ ์žฅ์œผ๋กœ ๋“ค์–ด์˜จ ํ˜ˆ๊ด€์˜ ํŽ˜์ƒ‰)
    • Postrenal : ์š”๊ฒฐ์„, TCC
  • Hallmark : oliguria or anuria with azotemia

  • Pathogeneiss

    • ์—ฌ๊ณผ์œจ์ด ๊ฐ์†Œํ•จ
    • ์„ธ๊ด€์— ๋ญ๊ฐ€ ์Œ“์ž„ โ†’ ์˜ฌ๋ผ๊ฐ€์„œ ๊ฐ„์งˆ ๋“ฑ์—๋„ ์˜ํ–ฅ ์ค„ ์ˆ˜ ์žˆ์Œ
    • ๋‚ด๊ฐ• ์–ด๋”˜๊ฐ€ ๋ง‰ํž ์ˆ˜ ์žˆ์Œ (์„ธ๋‡จ๊ด€ ํ๋ฆ„ ๋ง‰ํž˜)
    • ํ˜ˆ๊ด€ ์ˆ˜์ถ•์œผ๋กœ ์ธํ•ด perfusion ๊ฐ์†Œ
    • ์ผ์ฐ ํŒŒ์•…ํ•˜๊ณ  ๋ณด์ถฉํ•˜๋Š” ๊ฒƒ์ด ํšŒ๋ณต์˜ ์ค‘์š”ํ•œ ์š”์†Œ
CRF
  • ๋น„๊ฐ€์—ญ์ , ์ง„ํ–‰์„ฑ nephron lossd
  • endpointsz :glomemrulonephritis, chronic TIN, amyloidosis ๋ณด์ด๋ฉด ๋Šฆ์—ˆ๊ตฌ๋‚˜
  • ์ž„์ƒ ์ฆ์ƒ : ๋‹ค๋‡จ, ์ฒด์ค‘์†Œ์‹ค, ๋นˆํ˜ˆ,
  • ์ƒํ™”ํ•™์ ์œผ๋กœ๋Š” azotemia, hyerphosphatemia (์นผ์Š˜ phosphate๋ฅผ ํ˜•์„ฑํ•จ), ์žฌํก์ˆ˜์™€ ๋ฐฐ์ถœ ๋ฌธ์ œ๋กœ ๋Œ€์‚ฌ์„ฑ ์‚ฐ์ฆ
Systemic Effects
  • ์†Œํ™”๊ธฐ :
    • ulcerative & hemorrhagic gastritis (ํ˜ˆ๊ด€๋‚ดํ”ผ์„ธํฌ ์†์ƒ์‹œ์ผœ์„œ
    • ์•„์ฃผ ์‹ฌํ•œ ๊ตฌ์ทจ (์š”๋…์ฆuremia๋ฅผ ์˜์‹ฌํ•  ์ˆ˜ ์žˆ๋‹ค)
  • ์‹ฌํ˜ˆ๊ด€๊ณ„ :
  • ๋‚ดํ”ผ์„ธํฌ๋ผ๋ฆฌ ์—ฐ๊ฒฐ๋˜๊ฒŒ ํ•˜๋Š” ๋ฌผ์งˆ๋“ค๋„ uremia ๋…์†Œ์— ์˜ํ•ด ๋Š์–ด์ง โ†’ ํ˜ˆ๊ด€ํˆฌ๊ณผ์„ฑ ์ฆ๊ฐ€ โ†’
  • hypoplastic anemia : erythropoietin์ด ๋‚˜์˜ค์ง€ ์•Š์Œ
  • soft-tissue mineralization
  • ๋ผˆ๋Š” ๊ณ„์† ์นผ์Š˜์„ ์žƒ์–ด๋ฒ„๋ฆผ โ†’ ๊ฒฐํ•ฉ์กฐ์ง์ด ์—„์ฒญ ๋ฐœ๋‹ฌ, osteoblast๋„ ๊ณ„์† ์ž‘๋™,but ๋ฏธ์„ฑ์ˆ™ํ•œ ๊ณจ์กฐ์ง ํ˜•์„ฑ
ํ˜ˆ๊ด€ ํˆฌ๊ณผ์„ฑ์˜ ์ฆ๊ฐ€ โ†’ Pulmonary edema, Fibrinous pericarditis
Ulcerative and hemorrhagic gastritis ์‹ฌํ•œ ๊ตฌ์ทจ, ์œ„๊ถค์–‘, ์œ„์—ผ ๋“ฑ์„ ์œ ๋ฐœ. ํ˜ˆ๊ด€ ์†์ƒ์ด ใ…‡
Hypoplastic anemia (๋น„์žฌ์ƒ์„ฑ ๋นˆํ˜ˆ) : ์š”๋…์ฆ์˜ toxin์ด RBC๋“ค์„ ํŒŒ๊ดดํ•˜๊ณ , erythropoietin ๋ถ„๋น„๊ฐ€ ๊ฐ์†Œ โ†’ ๋น„์žฌ์ƒ์„ฑ
- Soft-tissue mineralization โ† calcium-phosphate๋ฅผ ํ˜•์„ฑํ•ด์„œ ์œ„, ํ, ์žฅ๋ง‰ ๋“ฑ์— ์นจ์ฐฉ
- Fibrous osteodystrophy โ† ๊ฒฐํ•ฉ์กฐ์ง์ด ๋น ๋ฅด๊ฒŒ ์ฑ„์šฐ๊ธฐ ์‹œ์ž‘ํ•˜๊ณ , ๊ณจ์กฐ์ง์„ ๋งŒ๋“ค์ง€๋งŒ ์นผ์Š˜์ด ์—†์–ด์„œ ๋ฏธ์„ฑ์ˆ™
- Parathyroid hyperplasia โ† free Ca2+ ์ค„์–ด๋“ค์–ด์„œ ๋ผˆ์—์„œ ๊ณ„์† ์นผ์Š˜ ์žฌํก์ˆ˜ โ† ๊ณ„์†

ํ‘œ๋Š” ๋‹ค ์•Œ์•„์•ผ ํ•จ! ๋งŒ์„ฑ ์‹ ๋ถ€์ „ ํ™˜์ž์—์„œ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋Š” ์ฆ์ƒ. Kidney์˜ ์ •์ƒ ๊ธฐ๋Šฅ์— ๊ธฐ๋ฐ˜ํ•˜์—ฌ ์•ˆ ๋ณด๊ณ ๋„ ์ž‘์„ฑํ•  ์ค„ ์•Œ์•„์•ผ.

End-stage kidney : ํˆฌ์„, ์‹ ์žฅ์ด์‹ but ํ˜„์‹ค์ ์œผ๋กœ ์–ด๋ ต๋‹ค ์ฒœ์ฒœํžˆ ๋‚˜๋น ์ง€๊ฒŒ ํ•˜๋Š” management๊ฐ€ ์ง€๊ธˆ ํ•  ์ˆ˜ ใ…ฃใ…=

6. Lower Urinary Tract Disorders

7. Urinary Tract Neoplasia

Key Concepts

  • ์••๋„์ ์œผ๋กœ TCC๊ฐ€ ๋งŽ์ด ์ƒ๊ธด๋‹ค.
    • ์š”๊ฒ€์‚ฌ๋ฅผ ํ†ตํ•ด, ํŠน์ • ์œ ์ „์ž์˜ mutation์ด ๋†’์€์ง€ ํ™•์ธํ•˜๋ฉด ์ •ํ™•ํ•œ ์ง„๋‹จ ๊ฐ€๋Šฅ
  • Other tumors : squamous cell carcioma, adenocarcinoma, nephroblastoma
  • ๊ฐœ > ๊ณ ์–‘์ด > ๋ฐ˜์ถ”๋ฅ˜ ์ˆœ์œผ๋กœ ๋ฐœ์ƒ์ด ๋†’๋‹ค
  • Paraneoplastic syndromes ๊ฐ€ ์žˆ๋‹ค, metastasis ๊ฐ€๋Šฅ์„ฑ์ด ๋†’๋‹ค, ์•…์„ฑ๋„๊ฐ€ ๋†’์€ ์ข…์–‘
  • Renal adenoma
  • Renal cell carcinoma (RCC) :

์ •์ƒ๊ตฌ์„ฑ์„ธํฌ๊ฐ€ ์ข…์–‘์ด ๋˜๋Š” ๊ฒƒ์ด๋ฏ€๋กœใ…—

  • ์š”์˜ ํ๋ฆ„์„ ๋ง‰๊ณ , ํ˜ˆ๋‡จ๊ฐ€ ์ƒ๊ธธ ์ˆ˜ ์žˆ๊ณ , obstruction โ†’ 2์ฐจ์  ๊ฐ์—ผ์— ์ทจ์•ฝํ•ด์งˆ ์ˆ˜ ์žˆ๋‹ค
Transitional Cell Carcinoma (TCC)
  • TCC(=urothelial cell carcinoma)๋Š” ๋ฐฉ๊ด‘์‚ผ๊ฐ(the bladder trigone) ์—์„œ ์ž˜ ์ƒ๊ธด๋‹ค.
  • ์นจ์Šต๊ณผ ์ „์ด๊ฐ€ ๋งค์šฐ ํ”ํ•˜๋‹ค (๊ตญ์†Œ ๋ฆผํ”„์ ˆ, ํ๊นŒ์ง€)
  • ์ ๋ง‰์ด ๋น„ํ›„๋˜๊ณ , ๋ถˆ๊ทœ์น™ํ•˜๋‹ค, 2์ฐจ์ ์œผ๋กœ ์ ๋ง‰์˜ ๊ถค์–‘๋„ ๊ด€์ฐฐ๋  ์ˆ˜ ์žˆ๋‹ค.
Others
  • ์ƒํ”ผ์„ธํฌ ์ข…์–‘
    • Squamous cell carcinoma : ์ €ํ•ญ์„ฑ ์žˆ๋Š” ์„ธํฌ๋กœ ๋ณ€ํ•˜๊ณ ์ž ํ•˜๋Š” metaplasia โ†’ ์ด๊ฒŒ ์ข…์–‘ํ™”๋˜์–ด squamous cell carcinoma (๋น„๋‡จ๊ธฐ์— squamous cell ์—†๋Š”๋ฐ, metaplasia ๋•Œ๋ฌธ)
    • Adenocarcinoma : ์‹ ์žฅ tubule์—์„œ ์ „์ด๋˜์–ด ์˜ด
    • Nephroblastoma
  • ์ค‘๋ฐฐ์—ฝ ์œ ๋ž˜ ์ข…์–‘
    • Leiomyoma/Leiomyosaracoma (ํ‰ํ™œ๊ทผ ์œ ๋ž˜)
    • Rhabdomyoma/Rhabdomyosarcoma (ํšก๋ฌธ๊ทผ ์œ ๋ž˜) ๋ฐ”๊นฅ์ชฝ์œผ๋กœ ๋ถˆ๊ทœ์น™ํ•˜๋ฉด, ๋ฒฝ์„ ํ˜•์„ฑํ•˜๋Š” ๊ทผ์œก ์ชฝ ์ข…์–‘์ด๊ฒ ๊ตฌ๋‚˜
Lymphoma

๋ฐฉ๊ด‘์—์„œ ์›๋ฐœ lymphoma๋Š” ๋งค์šฐ ๋“œ๋ฌผ๋‹ค.

์‹ ์žฅ์— ์ƒ๊ธด lymphoma๋Š” ์ „์ด๋˜์—ˆ์„ ๊ฐ€๋Šฅ์„ฑ์ด ํฌ๋‹ค.

  • ๋ง‰์•„์„œ renomegaly ์ •์ƒ ๋„คํ”„๋ก ์„ ๋Œ€์ฒดํ•˜๊ณ  ์žˆ์œผ๋ฏ€๋กœ renal failure, paraneoplastic hypercalcemia (PTH-rH ๋ถ„๋น„ํ•˜๋Š” ์ข…์–‘ ์ค‘ ํ•˜๋‚˜๊ฐ€ lymphoma)

(์ „์ดํŒจํ„ด) ํ•˜์–€์ƒ‰ ๊ฒฐ์ ˆ๋“ค์ด ์ค‘์š”ํ•˜๋‹ค

Tumor-like lesions
  • Eosinophilic polypoid cystitis : ๋ณผ๋ก๋ณผ๋กํ•œ ํ˜•ํƒœ,
  • Brunnโ€™s nest : ์ ๋ง‰์กฐ์ง์— ์›๋ž˜ ์ƒํ”ผ์„ธํฌ๊ฐ€ ์—†๋Š”๋ฐ,
    • โ‡’ ์žฅ๊ธฐ์ ์œผ๋กœ ๋ฐฉ๊ด‘์•”์ด ์ƒ๊ธธ ๊ฐ€๋Šฅ์„ฑ์ด ๋†’์•„์ง„๋‹ค- ์‚ฌ๋žŒ์—์„  ๊ทธ๋Ÿฐ๋ฐ, ๋™๋ฌผ์—์„œ๋Š” ์—ฐ๊ตฌ ๊ฒฐ๊ณผ ๋ถ€์กฑ
  • ์ƒํ”ผ์„ธํฌ๊ฐ€ ๋ฐ‘์œผ๋กœ ํŒŒ๊ณ ๋“ค๋“ฏ์ด ๊ณผ์ฆ์‹ (์นจ์ŠตX)
  • invagination
  • (์ƒํ”ผ์„ธํฌ๊ฐ€ ๋งˆ์น˜ ์ข…์–‘์ฒ˜๋Ÿผ ๋ณด์ผ ์ˆ˜ ์žˆ๋‹ค๋Š” ๊ฑฐ~)
  • ๊ฐœ : ์••๋„์ ์œผ๋กœ TCC
  • ๊ณ ์–‘์ด : TCC > lymphoma๋„ ์ข…์ข…
  • ์†Œ : TCC
  • ๋ผ์ง€ : nephroblastoma